Bio-Techne Corp (NASDAQ: TECH) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
This table compares Bio-Techne Corp and Global Blood Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Blood Therapeutics||N/A||-38.92%||-36.49%|
Insider and Institutional Ownership
98.4% of Bio-Techne Corp shares are owned by institutional investors. Comparatively, 86.1% of Global Blood Therapeutics shares are owned by institutional investors. 3.4% of Bio-Techne Corp shares are owned by insiders. Comparatively, 5.3% of Global Blood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and price targets for Bio-Techne Corp and Global Blood Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Blood Therapeutics||0||0||11||0||3.00|
Bio-Techne Corp presently has a consensus target price of $126.33, indicating a potential upside of 2.33%. Global Blood Therapeutics has a consensus target price of $55.73, indicating a potential upside of 74.15%. Given Global Blood Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Global Blood Therapeutics is more favorable than Bio-Techne Corp.
Volatility & Risk
Bio-Techne Corp has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 4.21, indicating that its stock price is 321% more volatile than the S&P 500.
Bio-Techne Corp pays an annual dividend of $1.28 per share and has a dividend yield of 1.0%. Global Blood Therapeutics does not pay a dividend. Bio-Techne Corp pays out 66.0% of its earnings in the form of a dividend.
Valuation and Earnings
This table compares Bio-Techne Corp and Global Blood Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Bio-Techne Corp||$563.00 million||8.20||$186.35 million||$1.94||63.64|
|Global Blood Therapeutics||N/A||N/A||-$95.43 million||($2.47)||-12.96|
Bio-Techne Corp has higher revenue and earnings than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Bio-Techne Corp, indicating that it is currently the more affordable of the two stocks.
Bio-Techne Corp beats Global Blood Therapeutics on 8 of the 14 factors compared between the two stocks.
Bio-Techne Corp Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company’s GBT440 is an investigational drug that increases hemoglobin’s affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.